Last reviewed · How we verify
NCT05070208: RETRO-CBF
Multicenter Retrospective Observatory of Patients With Acute Myeloid Leukemia to Core Binding Factor
trial testing NOT PROVIDED in Acute Myeloblastic Leukemia Core Binding Factor in 400 participants. Completed in 5 May 2024.
25 January 2024
Quick facts
| Lead sponsor | Acute Leukemia French Association |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 400 |
| Start date | 22 September 2021 |
| Primary completion | 25 January 2024 |
| Estimated completion | 5 May 2024 |
| Sites | 26 locations across France |
Drugs / interventions tested
- NOT PROVIDED
Conditions studied
- Acute Myeloblastic Leukemia Core Binding Factor — all drugs for Acute Myeloblastic Leukemia Core Binding Factor →
Sponsor
Acute Leukemia French Association
Who can join
18 and older, any sex, with Acute Myeloblastic Leukemia Core Binding Factor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Acute Core Binding Factor leukemias represent a specific category of acute myeloid leukemias that share prognostic factors, a specific mutational profile, and a favorable response to chemotherapy. Their management now follows the reference pattern from the French trial CBF-2006 closed to inclusions since November 2010. This includes intensive chemotherapy and intensification by allogeneic marrow transplant depending on the residual disease measured by RT qPCR . These leukemias have not been the subject of multicenter clinical trials since that date. The results of this treatment regimen need to be evaluated. Known prognostic factors such as signaling mutations, clonal interference or residual disease follow-up (MRD) will be analyzed and updated in this recent cohort. The interaction between residual disease and mutational profile will be evaluated on the prognosis. Treatment with gemtuzumab-ozogamycin and first-line allogeneic transplantation will be investigated, depending on prognostic factors including associated mutations and residual disease. The course and early treatment of molecular relapses will be analyzed. The treatment and prognosis of cytological relapses will be described with in particular the role of tyrosine kinase inhibitors and therapeutic intensification.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Genetic alterations and measurable residual disease in core binding factor acute myeloid leukemia.
Vasseur L, Duchmann M, Duployez N, Raffoux E, et al · · 2026 · PMID 41888395 · DOI 10.1038/s41375-026-02900-x
Verify or expand the search:
- PubMed search for NCT05070208
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Acute Leukemia French Association trials
Trials by the same sponsor.
- NCT04777916 — Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05070208 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Acute Leukemia French Association
- Last refreshed: 2 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05070208.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing